drugset / Trial / NCT07805135
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.
Timeline
- Start
- 2026-08-31
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | HB1801 | Unknown | 75 mg/m2 | Intravenous |